IC
ICLR.US ICON PLC
- Market cap
- USD 14.6B
- P/E
- 77.9x
- P/B
- 1.60x
- ROE
- 4.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ICLR.US undervalued?
Graham numberICLR.US trades 135.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ICON PLC fundamental analysis
No fundamental analysis for ICON PLC yet.
ICON PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of developmen…
Full company profileICON PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ICON PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.67B | 1.76B | 2.60B | 2.81B | 2.80B | 5.48B | 7.74B | 8.12B | 8.28B | 8.25B | 8.16B |
| Gross Profit | 705M | 727M | 769M | 832M | 808M | 1.51B | 2.21B | 2.40B | 2.44B | 2.18B | 1.69B |
| Operating Income | 312M | 338M | 373M | 433M | 392M | 379M | 795M | 956M | 1.10B | 1.01B | 758M |
| EBITDA | 379M | 402M | 452M | 502M | 489M | 694M | 1.37B | 1.52B | 1.56B | 824M | 1.18B |
| Net Income | 262M | 281M | 323M | 374M | 328M | 153M | 505M | 612M | 791M | 229M | 399M |
| EPS | 4.65 | 5.13 | 5.90 | 6.88 | 6.15 | 2.25 | 6.13 | 7.40 | 9.53 | 2.90 | 5.16 |
| Balance Sheet | |||||||||||
| Total Assets | 1.83B | 2.19B | 2.39B | 2.91B | 3.44B | 17.4B | 17.2B | 17.0B | 16.9B | 16.3B | 16.2B |
| Total Liabilities | 881M | 956M | 1,000M | 1.29B | 1.59B | 9.32B | 8.69B | 7.75B | 7.35B | 7.08B | 7.12B |
| Shareholders' Equity | 945M | 1.23B | 1.39B | 1.62B | 1.85B | 8.07B | 8.50B | 9.24B | 9.52B | 9.19B | 9.13B |
| Cash & Short-term Investments | 261M | 360M | 456M | 570M | 842M | 754M | 290M | 380M | 539M | 647M | 809M |
| Total Debt | 548M | 606M | 684M | 455M | 434M | 5.65B | 4.83B | 3.94B | 3.60B | 3.56B | 3.51B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 259M | 383M | 264M | 413M | 595M | 829M | 563M | 1.16B | 1.29B | 1.04B | 1.03B |
| Capital Expenditure | 42.6M | 28.0K | 48.4M | 50.6M | 51.1M | 93.8M | 142M | 141M | 168M | 174M | 147M |
| Free Cash Flow | 217M | 48.7M | 216M | 362M | 544M | 735M | 421M | 1.02B | 1.12B | 862M | 879M |
| Ratios | |||||||||||
| ROE | 27.7% | 22.9% | 23.3% | 23.1% | 17.7% | 1.9% | 5.9% | 6.6% | 8.3% | 2.5% | 4.4% |
| ROA | 14.4% | 12.9% | 13.5% | 12.9% | 9.5% | 0.9% | 2.9% | 3.6% | 4.7% | 1.4% | 2.5% |
| Net Profit Margin | 15.7% | 16.0% | 12.4% | 13.3% | 11.7% | 2.8% | 6.5% | 7.5% | 9.6% | 2.8% | 4.9% |
| Debt to Equity | 0.58x | 0.49x | 0.49x | 0.28x | 0.23x | 0.70x | 0.57x | 0.43x | 0.38x | 0.39x | 0.38x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ICON PLC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 35.8M | 0.43 | 7.1% |
| 2021 | - | - | - |
| 2020 | USD 13.2M | 0.25 | 4.0% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Aug 13, 2008.
Who owns ICON PLC
- Insiders 1.31%
- Institutions 98.69%
- Public & others 0.00%
- Shares outstanding 74.9M
- Free float 74.9M
Top funds holding ICLR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Artisan International Value Investor | 6.86M | 9.15% | +1.64% | Sep 2026 |
| Oakmark Select Investor | 2.73M | 3.64% | +15.19% | Sep 2026 |
| Sequoia ETF | 1.34M | 1.79% | 0.00% | Oct 2026 |
| Invesco Small Cap Value A | 1.27M | 1.70% | +16.09% | Sep 2026 |
| Ninety One GSF Glb Frchs I Acc USD | 1.25M | 1.66% | 0.00% | Jan 2026 |
| Invesco Value Opportunities A | 1.13M | 1.50% | +42.53% | Sep 2026 |
| Fidelity Low-Priced Stock | 973K | 1.30% | -0.06% | Aug 2026 |
| Vanguard Windsor Investor Shares | 936K | 1.25% | -20.54% | Sep 2026 |
| American Funds New Perspective A | 876K | 1.17% | 0.00% | Sep 2026 |
| Vanguard Explorer Inv | 828K | 1.11% | +1.04% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 785K | 1.05% | +16.07% | Sep 2026 |
| Invesco Comstock A | 776K | 1.04% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap Value I | 702K | 0.94% | +101.22% | Sep 2026 |
| Principal International Equity Inst | 653K | 0.87% | 0.00% | Sep 2026 |
| MFS Mid Cap Value A | 488K | 0.65% | -0.80% | Sep 2026 |
| Columbia Small Cap Growth Inst | 473K | 0.63% | 0.00% | Sep 2026 |
| Kempen Intl Fds MercLan Glbl Eq F | 430K | 0.57% | -1.22% | Sep 2026 |
| Fidelity Series Stk Selec Lg Cp Val | 422K | 0.56% | -6.80% | Sep 2026 |
| Fidelity Global Value Growth Eq MF | 402K | 0.54% | +18.12% | Aug 2026 |
| Fidelity Value | 380K | 0.51% | -2.99% | Sep 2026 |
Top institutions holding ICLR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Artisan Partners Limited Partnership | 8.64M | 11.53% | +4.32% | Jun 2026 |
| Wellington Management Company LLP | 5.32M | 7.10% | -10.03% | Jun 2026 |
| FMR Inc | 5.27M | 7.04% | +26.29% | Jun 2026 |
| Amvescap Plc. | 5.26M | 7.03% | +35.72% | Jun 2026 |
| Harris Associates L.P. | 4.47M | 5.96% | +2.68% | Jun 2026 |
| Brave Warrior Advisors LLC | 3.15M | 4.21% | +5.22% | Jun 2026 |
| Greenhaven Associates Inc | 3.10M | 4.14% | +54.84% | Jun 2026 |
| Principal Financial Group Inc | 2.94M | 3.92% | -0.46% | Sep 2026 |
| Massachusetts Financial Services Company | 2.11M | 2.81% | -22.83% | Jun 2026 |
| Ruane, Cunniff & Goldfarb L.P. | 2.05M | 2.73% | +25.30% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.67M | 2.23% | +31.67% | Sep 2026 |
| Boston Partners Global Investors, Inc | 1.62M | 2.16% | +94.07% | Jun 2026 |
| Trinity Street Asset Management LLP | 1.49M | 1.99% | -3.13% | Sep 2026 |
| AllianceBernstein L.P. | 1.38M | 1.84% | +2.50% | Jun 2026 |
| D. E. Shaw & Co LP | 1.36M | 1.81% | +13.23% | Jun 2026 |
| Earnest Partners LLC | 1.23M | 1.64% | -1.34% | Sep 2026 |
| Maple Rock Capital Partners, Inc. | 1.20M | 1.60% | +257.77% | Jun 2026 |
| 1832 Asset Management L.P | 1.19M | 1.59% | +0.14% | Jun 2026 |
| Brandes Investment Partners & Co | 1.19M | 1.58% | -17.37% | Jun 2026 |
| Capital World Investors | 1.11M | 1.48% | +0.11% | Jun 2026 |
ICON PLC company profile
- Company name
- ICON PLC
- Ticker
- ICLR.US
- Exchange
- USA Stocks
- Listed since
- May 15, 1998
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 40,250
- Fiscal year end
- December
- Address
- South County Business Park, Dublin, Ireland, D18 X5R3
- Phone
- 353 1 291 2000
- Website
- iconplc.com
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICON PLC management
10- Mr. Barry BalfeCEO & Director · born 1979
- Dr. John Climax Ph.D.Founder & Independent Non-Executive Director · born 1953
- Mr. Nigel Clerkin A.C.A.Chief Financial Officer · born 1974
- Mr. Steve EmpolitiChief Commercial Officer
- Lyons EmerChief Accounting Officer
- Mr. Thomas N. O'LearyChief Information Officer
- Mr. Diarmaid CunninghamChief Administrative Officer, General Counsel & Company Secretary · born 1975
- Ms. Niamh MurphyDirector of Corporate Communications
- Mr. David GreenVice President of Marketing
- Mr. Joe CroninChief Human Resources Officer